The Haystack Project
  • Home
  • About Us Participants Partners Board and Advisors
  • Priorities
  • PROTECT Rare
  • Modernizing-FDA HEART Act
  • Speaker Series Payer Engagement Health Equity Patient Oriented Value Rare Cancer
  • Inflation Reduction Act Medicare Section 340b Medicaid FDA ICER
  • Patient Stories
  • Join
  • Take Action
The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Modernizing-FDA
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Patient Oriented Value
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
Blue-Banner.png
The Haystack Project

Resources

The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Modernizing-FDA
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Patient Oriented Value
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
November 28, 2022

Finance Democrats Call for More Consumer Protections in Medicare Advantage→

November 28, 2022/ Michelle Osburn

Read more.

November 28, 2022/ Michelle Osburn/ /Source
medicare

Michelle Osburn

November 18, 2022

Haystack's Comments to Congressional Leadership on HEART Act Provisions→

November 18, 2022/ Michelle Osburn

Read more.

November 18, 2022/ Michelle Osburn/ /Source
Comment Letters
news, HEART Act

Michelle Osburn

November 07, 2022

Haystack's comments to CMS on Streamlining Renewal Processes→

November 07, 2022/ Michelle Osburn

Read more.

November 07, 2022/ Michelle Osburn/ /Source
Comment Letters
medicaid, cms

Michelle Osburn

November 03, 2022

Haystack Response to CMS' Make Your Voice Heard RFI→

November 03, 2022/ Michelle Osburn

Read here.

November 03, 2022/ Michelle Osburn/ /Source
Letters
other issues, medicare, medicaid

Michelle Osburn

September 28, 2022

Haystack Comments to AHRQ on CED Recommendations Protecting Patients→

September 28, 2022/ Michelle Osburn

Read more.

September 28, 2022/ Michelle Osburn/ /Source
Comment Letters
rare, cancer, Comments to AHRQ

Michelle Osburn

September 13, 2022

Haystack signs on to Telehealth Stakeholder Letter to Senate→

September 13, 2022/ Michelle Osburn

Read more.

September 13, 2022/ Michelle Osburn/ /Source
Comment Letters
telehealth, Medicare

Michelle Osburn

September 07, 2022

FDA needs to be more flexible assessing rare →

September 07, 2022/ Michelle Osburn

Read more.

September 07, 2022/ Michelle Osburn/ /Source
Patient Stories
news

Michelle Osburn

September 06, 2022

Haystack Project highlights the need for well-meaning proposals to consider impact on rare patients. →

September 06, 2022/ Michelle Osburn

Read more.

September 06, 2022/ Michelle Osburn/ /Source
Comment Letters
medicaid, medicare, IRA

Michelle Osburn

August 01, 2022

Haystack Responds to HHS RFI on Improving Primary Care

August 01, 2022/ Michelle Osburn

Read more.

August 01, 2022/ Michelle Osburn/ /Source
Comment Letters, Letters
miscellaneous, Medicare, Medicaid

Michelle Osburn

June 17, 2022

Haystack Project's reply to CMS' Hospital Inpatient Prospective Payment Systems→

June 17, 2022/ Michelle Osburn

Read more.

June 17, 2022/ Michelle Osburn/ /Source
Letters
medicare, news

Michelle Osburn

June 14, 2022

Press Release: Haystack Project Applauds the Inclusion of the HEART Act in the User Fee Package→

June 14, 2022/ Michelle Osburn

Read more.

June 14, 2022/ Michelle Osburn/ /Source
Reports
HEART Act, news

Michelle Osburn

June 01, 2022

The Access to Rare Indications Act could be a game-changer for millions of Americans→

June 01, 2022/ Michelle Osburn

Read more.

June 01, 2022/ Michelle Osburn/ /Source
rare

Michelle Osburn

May 20, 2022

Comments on Senate HELP Committee May 2022 Draft UFA Package→

May 20, 2022/ Michelle Osburn

Read more.

May 20, 2022/ Michelle Osburn/ /Source
Letters, Comment Letters
HELP, HEART Act

Michelle Osburn

April 29, 2022

April 2022 Newsletter→

April 29, 2022/ Michelle Osburn

Read here.

April 29, 2022/ Michelle Osburn/ /Source

Michelle Osburn

April 29, 2022

Haystack's AA Pathway "Reforms"

April 29, 2022/ Michelle Osburn

Read more.

April 29, 2022/ Michelle Osburn/ /Source
Position Statements
advocacy, other issues

Michelle Osburn

April 28, 2022

New bill calls for more data and new development approaches on orphan drug development→

April 28, 2022/ Michelle Osburn

Read more.

April 28, 2022/ Michelle Osburn/ /Source
news

Michelle Osburn

March 07, 2022

STAT on Access to Rare Indications Act

March 07, 2022/ Michelle Osburn

Read more here.

March 07, 2022/ Michelle Osburn/ /Source
news, rare

Michelle Osburn

February 24, 2022

Patient Group Support letter for the Access to Rare Indications Act (HR 6160)→

February 24, 2022/ Michelle Osburn

Read more.

February 24, 2022/ Michelle Osburn/ /Source

Michelle Osburn

February 22, 2022

Access to Rare Indications: Ensure Rare Disease Parity in Accessing Medically Necessary Care in Medicare and Medicaid→

February 22, 2022/ Michelle Osburn

Read more.

February 22, 2022/ Michelle Osburn/ /Source

Michelle Osburn

February 21, 2022

Rep. Matsui releases "Dear Colleagues" letter, asking for co-sponsors for HR6160.→

February 21, 2022/ Michelle Osburn

Read more.

February 21, 2022/ Michelle Osburn/ /Source
Letters
rare

Michelle Osburn

  • Previous
  • Next

About Us

The Issues

Resources

News & Updates

© 2020 Haystack Project. All Rights Reserved. 

 

Contact Us

Please consider making a tax-deductible donation to support the Haystack Project today.

The Haystack Project is a 501(c)3 nonprofit that brings together patients organizations representing patients suffering from or caring for patients with extremely rare diseases. Our mission is to educate policymakers and other stakeholders about the need for policies that recognize the unique circumstances of extremely rare conditions and treatments and expand incentives critical to ensuring they can reach patients.